The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at treating individuals with Angelman syndrome (AS), a rare ...

Background/aim Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are rare imprinting disorders caused by the aberrant ...

A new review sheds light on the complex molecular mechanisms behind Angelman syndrome (AS), a rare neurogenetic disorder, and ...

Columbus, Ohio (WSYX) — Representative Warren Davidson, a Republican from Ohio, on Thursday introduced the Trump Derangement Syndrome (TDS) Research Act of 2025. The proposed legislation aims to ...

Epilepsy is highly heritable, with numerous known genetic risk loci. However, the genetic predisposition’s role in poststroke epilepsy (PSE) remains understudied. This study assesses whether a higher ...

Tahar Rajab is a Newsweek News and Features Journalist based in London, UK. His focus is audience engagement, traffic growth and analytics. He has covered a wide range of topics from world news to ...

For decades, Eve Baer remained convinced that her son, unresponsive after a severe brain injury, was still conscious. Science ...

Abstract: West syndrome (WS) is a neurodevelopmental disorder causing retardation in many patients. Hypsarrhythmia electroencephalography (EEG) and motor spasms are considered as clinical ...

Partly to mostly cloudy overnight with some light showers, drizzle and fog possible in some areas. Lows will drop into the 30s, 40s and 50s. Wednesday will be slightly warmer with a chance for ...

“Finally, they did a neurological test and then they did some genetic testing, and then that’s when they realized, okay, he’s got Angelman syndrome,” said Emanuel. Finally, the Prodans had ...